SU-5402

N/A

Report date: 2022/06/10 17:19:16

NME

Base Information

Drug NameSU-5402

Drug Alias NameSU-5402

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionVascular endothelial growth factor receptor 2 antagonistsFibroblast growth factor receptor 1 antagonistsPlatelet-derived growth factor receptor beta inhibitors

TargetsVascular endothelial growth factor receptor 2Fibroblast growth factor receptor 1Platelet-derived growth factor receptor beta

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesNew York University School Of Medicine

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesNew York University School Of Medicine

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A